Compare Abbott Laboratories (ABT) vs AXT Inc (AXTI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs AXT Inc — how do they compare? Abbott Laboratories trades at $95.13 (market cap $166.94B), while AXT Inc trades at $60.55 (market cap $3.80B). The key difference: Abbott Laboratories is far larger — about 43.9× AXT Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while AXT Inc pays none. Which is the better fit depends on your goals.
| ABT | AXTI | |
|---|---|---|
Market Cap | $166.94B | $3.80B |
Sector | Health | Technology |
52-Week High | $136.62 | $140.83 |
52-Week Low | $82.57 | $1.92 |
Enterprise Value | $193.69B | $3.77B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
AXTI trades at $63.52, up 12.19% today, but remains in a bearish technical trend with support at $60 and resistance at $64. The company reported a net loss of $21.26M in 2025 despite revenue of $88.33M, though 2026 projections show improving margins. Recent news highlights strong AI-driven demand for indium phosphide and a record $100M backlog, with earnings scheduled for July 30, 2026.
Outlook is mixed: analyst consensus is bullish (64% buy ratings) based on AI growth potential, but profitability challenges and geopolitical risks in China pose significant headwinds. The stock's high P/S ratio of 30.7 suggests premium valuation despite current losses, making execution critical for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About AXT Inc
AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.
Read more on AXTI →
